Kite Pharma Financials
Based on the key measurements obtained from Kite Pharma's financial statements, Kite Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in May.
With this module, you can analyze Kite financials for your investing period. You should be able to track the changes in Kite Pharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Kite |
Understanding current and past Kite Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kite Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Kite Pharma's assets may result in an increase in income on the income statement.
The data published in Kite Pharma's official financial statements usually reflect Kite Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kite Pharma. For example, before you start analyzing numbers published by Kite accountants, it's critical to develop an understanding of what Kite Pharma's liquidity, profitability, and earnings quality are in the context of the Kite space in which it operates.
Please note, the presentation of Kite Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kite Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kite Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kite Pharma. Please utilize our Beneish M Score to check the likelihood of Kite Pharma's management manipulating its earnings.
Kite Pharma Stock Summary
Kite Pharma competes with IPG Photonics, Eterna Therapeutics, Microchip Technology, Kaltura, and Micron Technology. Kite Pharma, Inc., a clinicalstage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products.| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| Business Address | 2225 Colorado Avenue, |
| Benchmark | NYSE Composite |
| Website | www.kitepharma.com |
| Phone | 310 824 9999 |
You should never invest in Kite Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kite Stock, because this is throwing your money away. Analyzing the key information contained in Kite Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Kite Pharma Key Financial Ratios
Generally speaking, Kite Pharma's financial ratios allow both analysts and investors to convert raw data from Kite Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Kite Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Kite Pharma reports annually and quarterly.| Return On Equity | -0.0063 | |||
| Return On Asset | -1.0E-4 | |||
| Number Of Employees | 184 |
Kite Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kite Pharma's current stock value. Our valuation model uses many indicators to compare Kite Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kite Pharma competition to find correlations between indicators driving Kite Pharma's intrinsic value. More Info.Kite Pharma is rated fourth overall in return on equity category among related companies. It is rated fourth overall in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kite Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kite Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kite Pharma's earnings, one of the primary drivers of an investment's value.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Kite Stock
If you are still planning to invest in Kite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kite Pharma's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |